Introduction {#sec1-1}
============

Cancer, a major public health issue, is a leading cause of death worldwide. It has been estimated that more than 14.1 million new cases and 8.2 million cancer-related deaths happened annually (Siegel et al., 2016). Cancer is recognized as a multifactorial disease resulting from the integration between genetic and environmental factors (Lichtenstein et al., 2000). Single-nucleotide polymorphisms (SNPs) and small insertions or deletions (indels) are the most common genetic variations in human genome (Hashemi et al., 2018). Several studies showing the association between functional SNPs in various genes and the risk of developing cancer.

Adipokines, such as resistin, leptin, adiponectin and visfatin, are mainly synthesized in white adipose tissue and have been related to the pathogenesis of autoimmune disease, inflammatory diseases and cancer (John et al., 2006; Salageanu et al., 2010; Riondino et al., 2014; Muppala et al., 2017; Li and Han, 2018).

Resistin is a 12.5-kDa cysteine-rich polypeptide that upregulates the expression of proinflammatory cytokines and helps expand the population of regulatory T cells (Steppan et al., 2001; Bokarewa et al., 2005). The *RETN* gene encode resistin is mapped to chromosome 9 (19p13.2). Resistin is increased in type 2 diabetes and is closely correlated with insulin resistance and obesity (Shuldiner et al., 2001; Steppan et al., 2001; John et al., 2006). Obesity is well recognized as a risk factor for colorectal cancer development (Joshi et al., 2014; Joshi and Lee, 2014). Resistin may also be involved in the pathogenesis of cancer (Gonullu et al., 2010; Danese et al., 2012; Riondino et al., 2014). The serum levels of resistin have been shown to be higher in colorectal cancer (CRC) (Kumor et al., 2009; Gonullu et al., 2010; Nakajima et al., 2010; Danese et al., 2012; Slomian et al., 2017), and breast cancer (Dalamaga et al., 2013; Assiri et al., 2015; Deshmukh et al., 2015; Assiri and Kamel, 2016; Zeidan et al., 2018) than controls subjects.

Previous studies also demonstrated that the *RETN* gene variants were associated with the regulation of *RETN* gene expression and serum levels of resistin (Cho et al., 2004; Osawa et al., 2004).

In the last few years, a number of studies on the association between REST gene polymorphisms and risk of cancer have been published, with controversial results (Wagsater et al., 2008; Pechlivanis et al., 2009; Al-Harithy and Al-Ghafari, 2010; Alharithy, 2014; Mahmoudi et al., 2014; Duzkoylu et al., 2015; Mahmoudi et al., 2016; Hu et al., 2017; Kohan, 2017; Munoz-Palomeque et al., 2018). Therefore, we conducted a meta-analysis to exactly establish the association between *RETN* rs1862513 C\>G (-420 C\<G) and rs3745367 (+299 G\>A gene polymorphisms and the risk of cancer.

Literature search {#sec2-1}
-----------------

Literature searching in the databases such as PubMed, Web of Science, Scopus, and Google Scholar was performed for all articles describing an association between resistin polymorphisms and cancer risk published up to April 2018. Comprehensive search strategies involved the Mesh term and ('resistin' or '*RETN*'), ('polymorphism' or 'variant' or 'genotype' or 'SNP' or 'mutations'), ('cancer' or 'tumor'). Relevant studies which were eligible for the meta-analysis must meet the following criteria: 1) Original case-control studies of the correlation between the *RETN* polymorphisms and cancer 2) studies provided sufficient information of the genotype frequencies of *RETN* polymorphisms in both cases and controls. The criteria for exclusion were: 1) the articles have described case reports, reviews, overlapped data, animal or mechanism studies for *RETN* polymorphisms and cancer; 2) no genotype frequency or genotype information were provided for *RETN* polymorphism and cancer.

Data extraction {#sec2-2}
---------------

The papers were reviewed by two independent researchers. The following data were collected from each study such as the first author's last name, publication year, ethnicity, the sample size, and the genotype and allele frequencies of cases and controls.

Statistical analysis {#sec2-3}
--------------------

Meta-analysis was carried out using Revman 5.3 software (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and STATA 14.1 software (Stata Corporation, College Station, TX, USA). Hardy-Weinberg Equilibrium (HWE) in the control group was tested by χ^2^ test. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using forest-plots graphs to evaluate the association between *RETN* polymorphisms and cancer. The significance of the pooled OR was determined with the Z-test, and P-values \< 0.05 were considered statistically significant. Heterogeneity among studies was assessed using the I^2^ statistic and the χ^2^ test-based Q statistic. A p\< 0.10 and an I^2^ \> 50% indicated significant heterogeneity. Once heterogeneity existed among studies, a random-effect model was applied; otherwise a fixed-effect model was used.

Publication bias was assessed by funnel plot. The degree of asymmetry was measured using Egger's linear regression test; p \< 0.05 was considered significant publication bias.

Sensitivity analysis {#sec2-4}
--------------------

Sensitivity analysis was achieved using the method of eliminating studies one by one to verify whether our results were influenced by each included study or not.

Results {#sec1-2}
=======

Study characteristics {#sec2-5}
---------------------

10 studies met all the inclusion criteria and were included in this meta-analysis. Characteristics of the eligible studies are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of the Included Studies on RETN rs1862513 and rs3745367 Polymorphisms and Risk of Cancer

  First Author        Year   Country          Ethnicity   Cancer type         Source of control   Genotyping Method   Case/ controls   Genotype and allele distribution of cases and controls   HWE (p)                                                  
  ------------------- ------ ---------------- ----------- ------------------- ------------------- ------------------- ---------------- -------------------------------------------------------- --------- ---- ----- ----- ----- ----- ---- ------ ----- ---------
  rs1862513                                                                                                                            CC                                                       CG        GG   C     G     CC    CG    GG   C      G     
   Al-Harithy         2010   Saudi Arabia     Asian       Colon cancer        HB                  PCR- RFLP           60/6             16                                                       33        11   65    55    24    20    16   68     52    0.013
   Alharithy          2014   Saudi Arabia     Asian       Colon cancer        HB                  PCR- RFLP           60/6             15                                                       33        12   63    57    24    20    16   68     52    0.013
   Duzkoylu           2015   Turkey           Caucasian   Colorectal cancer   HB                  PCR- RFLP           123/79           53                                                       61        9    167   79    31    36    12   98     60    0.771
   Hu                 2017   China            Asian       Lung cancer         HB                  Real- time PCR      371/451          164                                                      157       50   485   257   182   203   66   567    335   0.444
   Kohan              2017   Iran             Asian       Breast cancer       HB                  PCR- RFLP           150/15           50                                                       63        37   163   137   63    63    24   189    111   0.225
   Mahmoudi           2014   Iran             Asian       Colorectal cancer   HB                  PCR- RFLP           197/217          38                                                       83        76   159   235   56    85    76   197    237   0.002
   Munoz- Palomeque   2018   Mexico           Caucasian   Breast cancer       PB                  PCR- RFLP           100/308          53                                                       42        5    148   52    199   102   7    500    116   0.144
   Pechlivanis        2009   Czech Republic   Caucasian   Colorectal cancer   HB                  PCR- RFLP           642/714          317                                                      262       63   896   388   393   265   56   1051   377   0.230
   Wagsater           2008   Sweden           Caucasian   Colorectal cancer   HB                  Taqman              248/256          127                                                      95        26   349   147   137   103   16   377    135   0.563
  rs3745367                                                                                                                            GG                                                       GA        AA   G     A     GG    AG    AA   G      A     HWE (p)
   Alharithy          2014   Saudi Arabia     Asian       Colon cancer        HB                  PCR- RFLP           60/6             3                                                        51        6    57    63    15    39    6    69     51    0.011
   Hu                 2017   China            Asian       Lung cancer         HB                  Real- timePCR       371/451          164                                                      164       43   492   250   190   194   67   574    328   0.134
   Mahmoudi           2016   Iran             Asian       Colorectal cancer   HB                  PCR- RFLP           312/438          65                                                       72        35   202   142   78    86    26   242    138   0.767

For *rs1862513* polymorphism, data from 9 studies including 1951 cancer patients and 2,295 healthy controls were included in this meta-analysis. Regarding *rs3745367* polymorphism, data from 3 studies containing 603 cases and 701 controls were included in this meta-analysis.

Quantitative synthesis {#sec2-6}
----------------------

All the calculated results were summarized in [Table 2](#T2 T3){ref-type="table"}. Our meta-analysis revealed that *rs1862513* polymorphism of *RETN* significantly increased the risk of cancer in codominant (OR=1.23, 95%CI= 1.01-1.50, p=0.04, CG vs CC; and OR=1.25, 95%CI= 1.03-1.53, p=0.03, GG vs CC), dominant (OR=1.19, 95%CI= 1.05-1.35, p=0.006, CG+GG vs CC), and allele (OR=1.14, 95%CI= 1.00-1.30, p=0.04, G vs C) inheritance genetic models ([Figure 1](#F1){ref-type="fig"} and [Table 2](#T2){ref-type="table"}).

###### 

The Pooled ORs and 95%CIs for the Association between RETN Polymorphisms and Cancer Susceptibility

  Polymorphism     Association test   Heterogeneity test   Egger's test P   Begg's test P                        
  ---------------- ------------------ -------------------- ---------------- --------------- ---- ------- ------- -------
  rs1862513 C\>G                                                                                                 
   CG vs CC        1.23 (1.01-1.50)   2.05                 0.04             14.00           43   0.08    0.891   0.532
   GG vs CC        1.25 (1.03-1.53)   2.21                 0.03             13.10           39   0.11    0.607   0.621
   CG+GG vs CC     1.19 (1.05-1.35)   2.74                 0.006            13.24           40   0.10    0.451   0.211
   GG vs CG+CC     1.11 (0.85-1.35)   0.75                 0.45             14.01           43   0.08    0.926   0.118
   CG vs GG+CC     1.17 (0.97-1.40    1.68                 0.09             13.86           42   0.09    0.153   0.466
   G vs C          1.14 (1.00-1.30)   2.01                 0.04             13.58           41   0.09    0.520   0.532
  rs3745367 G\>A                                                                                                 
   AG vs GG        1.32 (0.72-2.45)   0.90                 0.37             7.80            74   0.002   0.407   0.602
   AA vs GG        1.38 (0.60-3.17)   0.76                 0.44             7.67            74   0.02    0.883   0.117
   AG+GG vs AA     1.34 (0.73-2.46)   0.96                 0.34             8.43            76   0.01    0.368   0.602
   AA vs AG+GG     1.05 (0.60-1.84)   0.18                 0.92             4.69            57   0.10    0.193   0.117
   AG vs AA+GG     1.19 (0.74-1.93)   0.73                 0.47             6.34            68   0.04    0.679   0.602
   A vs G          1.11 (0.83-1.50)   0.71                 0.48             5.43            63   0.07    0.187   0.117

###### 

Stratified Analysis of RETN rs1862513 C\>G Polymorphism on Cancer Susceptibility

  Type of cancer       NO.   CG vs CC           GG vs CC   CG+GG vs CC        GG vs CG+CC   CG vs GG+CC        G vs C                                                                          
  -------------------- ----- ------------------ ---------- ------------------ ------------- ------------------ -------- ------------------ ------ ------------------ ------ ------------------ -------
  Cancer type                                                                                                                                                                                  
   Colorectal cancer   6     1.25 (1.06-1.47)   0.009      1.31 (1.02-1.68)   0.04          1.25 (1.07-1.46)   0.005    1.01 (0.72-1.43)   0.93   1.19 (1.02-1.39)   0.03   1.16 (1.03-1.30)   0.01
   Breast cancer       2     1.41 (0.99-1.99)   0.05       2.07 (1.18-3.63)   0.01          1.53 (1.10-2.13)   0.01     1.80 (1.07-3.02)   0.03   1.20 (0.87-1.67)   0.26   1.47 (1.15-1.87)   0.002
   Lung cancer         1     0.86 (0.64-1.15)   0.31       0.84 (0.55-1.28)   0.42          0.85 (0.65-1.13)   0.27     0.91 (0.61-1.35)   0.64   0.90 (0.68-1.7)    0.44   0.90 (0.73-1.10)   0.29
  Ethnicities                                                                                                                                                                                  
   Asian               5     1.42 (0.94-2.14)   0.10       1.19 (0.91-1.55)   0.21          1.33 (0.94-1.89)   0.11     1.05 (0.83-1.32)   0.70   1.27 (0.89-1.81)   0.81   1.09 (0.95-1.24)   0.24
   Caucasian           4     1.19 (1.00-1.41)   0.05       1.31 (0.75-2.30)   0.35          1.22 (1.04-1.43)   0.02     1.23 (0.71-2.11)   0.46   1.14 (0.97-1.35)   0.11   1.18 (1.04-1.34)   0.01

![Forest Plot of the Risk of Cancer Associated with RETN rs1862513 Polymorphism under Codominant Heterozygous Model (A), Codominant Homozygous Model (B), Dominant Model (C), Reccesive Model (D), Ovedominanat Model (E), and Allelic Model (F).](APJCP-19-2709-g001){#F1}

Stratification analysis by cancer type showed that *rs1862513* variant significantly increased the risk of colorectal cancer as well as breast cancer ([Table 2](#T2){ref-type="table"}).

As shown in [Table 2](#T2){ref-type="table"}, the *rs1862513* variant significantly increased the risk of cancer in Caucasian in dominant (OR=1.22, 95% CI= 1.04-1.43, p=0.02, CG+GG vs CC) and allele (OR=1.18, 95% CI= 1.04-1.34, p=0.01, G vs C) genetics model.

Regarding *rs3745367* variant, the finding showed no significant association between the variant and cancer risk ([Table 2](#T2){ref-type="table"}).

Publication bias {#sec2-7}
----------------

The potential publication bias was assessed using a Begg's funnel plot ([Figure 2](#F2){ref-type="fig"}) and Egger's test ([Table 2](#T2){ref-type="table"}). Begg's and Egger's tests proposed no evident publication bias in codominant, dominant recessive, overdominant, and allele inheritance models.

![Begg's Funnel Plot for Publication Bias Test for RETN rs1862513 Polymorphism. Each point represents a separate study for the indicated association. (A), heterozygous model; (B), codominant homozygous model; (C), dominant model; (D), reccesive model; (E), ovedominanat model; (F), allelic model.](APJCP-19-2709-g002){#F2}

Sensitivity analysis {#sec2-8}
--------------------

To verify the outcome of our analyses, we conducted a sensitivity analysis by excluding studies one by one, and then calculating the pooled estimate for the remaining studies ([Figure 3](#F3){ref-type="fig"}). The sensitivity analysis proposed that certain studies significantly affect the association between *RETN* polymorphism and risk of cancer. We believe that the small number of studies included in our meta-analysis may contribute to the influence of the abovementioned studies; if more studies had been included, the influence of any one study would be decreased.

![Results of Sensitivity Analysis of the Entire Database under Codominant Heterozygous Model (A), Codominant Homozygous Model (B), Dominant Model (C), Reccesive Model (D), Ovedominanat Model (E), and Allelic Model (F).](APJCP-19-2709-g003){#F3}

Discussion {#sec1-3}
==========

Cancer is a complex disease and it has been proposed that individual genetic variants may only have a modest independent effect on the disease. Adipokines, secreted by the adipose tissue, are convincing candidates for the relationship between obesity and cancer risk (Guadagni et al., 2009; Li et al., 2017; Zhang et al., 2017; Malvi et al., 2018). Obesity leads to insulin resistance and hyperinsulinemia, and insulin levels are positively correlated with colorectal cancer risk (Schoen et al., 1999; Giovannucci, 2007).

Up to now, a number of studies have been carefully designed and investigated the effect of genetic polymorphisms of *RETN* gene on the risk of cancer. Most of these studies were based on a small sample size and the findings were inconsistent (Wagsater et al., 2008; Pechlivanis et al., 2009; Al-Harithy and Al-Ghafari, 2010; Alharithy, 2014; Mahmoudi et al., 2014; Duzkoylu et al., 2015; Mahmoudi et al., 2016; Hu et al., 2017; Kohan, 2017; Munoz-Palomeque et al., 2018). This is the first meta-analysis conducted to specify the effect of *RETN* *rs1862513* and *rs3745367* polymorphisms on susceptibility to cancer. Data from 9 studies indicated that *RETN rs1862513* variant significantly increased the risk of cancer in codominant, dominant, and allele inheritance genetic models. We did not find any publication bias, which shows the reliability of the pooled results. Heterogeneity across studies suggests that there is a variation among the outcomes of studies than expected by chance. Sensitivity analysis also revealed an evidence of heterogeneity.

Stratified analyses based on cancer type showed that the *rs1862513* variant significantly increased the risk of colorectal cancer as well as breast cancer.

The *rs1862513* (-420 C\>G) polymorphism is located in the promoter region of *RETN* and has been shown to be associated with *RETN* protein expression (Cho et al., 2004; Osawa et al., 2004).

The *RETN* is a polymorphic and a functional polymorphism at -420 (*rs186513*) affects promoter activity and increases the expression of resistin. The molecular mechanism by which resistin affect cancer risk is not fully understood.

Regarding *rs3745367* variant, data from 3 studies did not support an association between variant and risk of cancer.

A significant deviation from HWE was found in 3 studies included the meta-analysis (Al-Harithy and Al-Ghafari, 2010; Alharithy, 2014). There is no clear clarification for deviation from HWE. The possible cause may be due to genetic drift.

In summary, our metanalysis investigation showed that rs1862513 polymorphism of *RETN* is a risk factor for cancer development. More studies with larger sample sizes are necessary to clarify the possible roles of *RETN* polymorphisms in cancer.
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